Scott  Gottlieb net worth and biography

Scott Gottlieb Biography and Net Worth

Director of Pfizer

Partner, New Enterprise Associates, Inc.’s Healthcare Investment Team and Resident Fellow of the American Enterprise Institute since 2019. Served as the 23rd Commissioner of the FDA from 2017 to 2019. Prior to serving as Commissioner of the FDA, Dr. Gottlieb held several roles in the public and private sectors, including serving as a Venture Partner to New Enterprise Associates, Inc. from 2007 to 2017.

Director of Illumina, Inc. Director of Aetion, Inc. a private healthcare data technology company, and Tempus, a private technology company. Board Member of National Resilience, Inc. Scientific Advisory Board Member of CellCarta. Member of the National Academy of Medicine and a contributor to the financial news network CNBC.

What is Scott Gottlieb's net worth?

The estimated net worth of Scott Gottlieb is at least $236,430.00 as of December 15th, 2023. Dr. Gottlieb owns 9,000 shares of Pfizer stock worth more than $236,430 as of April 23rd. This net worth evaluation does not reflect any other investments that Dr. Gottlieb may own. Learn More about Scott Gottlieb's net worth.

How do I contact Scott Gottlieb?

The corporate mailing address for Dr. Gottlieb and other Pfizer executives is 235 EAST 42ND STREET, NEW YORK NY, 10017. Pfizer can also be reached via phone at (212) 733-2323. Learn More on Scott Gottlieb's contact information.

Has Scott Gottlieb been buying or selling shares of Pfizer?

Scott Gottlieb has not been actively trading shares of Pfizer during the past quarter. Most recently, on Friday, December 15th, Scott Gottlieb bought 3,000 shares of Pfizer stock. The stock was acquired at an average cost of $26.47 per share, with a total value of $79,410.00. Following the completion of the transaction, the director now directly owns 9,000 shares of the company's stock, valued at $238,230. Learn More on Scott Gottlieb's trading history.

Who are Pfizer's active insiders?

Pfizer's insider roster includes Ronald Blaylock (Director), Albert Bourla (DVM), Loretta Cangialosi (VP), William Carapezzi, Jr. (EVP), Albert D.V.M. (DVM), Frank Damelio (EVP), Frank D'Amelio (CFO & Exec. VP ), Jennifer Damico (SVP), Jennifer Damico (SVP), Scott Gottlieb (Director), Rady Johnson (Insider), Douglas Lankler (EVP), Alexander Mackenzie (EVP), Laurie Olson (Insider), Ian Read (CEO), Dawn Rogers (EVP), Sally Susman (Insider), and John Young (Insider). Learn More on Pfizer's active insiders.

Are insiders buying or selling shares of Pfizer?

In the last year, Pfizer insiders bought shares 3 times. They purchased a total of 5,000 shares worth more than $156,410.00. The most recent insider tranaction occured on December, 15th when Director Scott Gottlieb bought 3,000 shares worth more than $79,410.00. Insiders at Pfizer own 0.1% of the company. Learn More about insider trades at Pfizer.

Information on this page was last updated on 12/15/2023.

Scott Gottlieb Insider Trading History at Pfizer

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/15/2023Buy3,000$26.47$79,410.009,000View SEC Filing Icon  
5/8/2023Buy1,000$38.58$38,580.006,000View SEC Filing Icon  
5/5/2023Buy1,000$38.42$38,420.005,000View SEC Filing Icon  
1/30/2020Buy1,000$37.15$37,150.004,000View SEC Filing Icon  
8/23/2019Buy3,000$34.72$104,160.003,000View SEC Filing Icon  
See Full Table

Scott Gottlieb Buying and Selling Activity at Pfizer

This chart shows Scott Gottlieb's buying and selling at Pfizer by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Pfizer Company Overview

Pfizer logo
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Read More

Today's Range

Now: $26.27
Low: $26.19
High: $26.47

50 Day Range

MA: $27.08
Low: $25.39
High: $28.37

2 Week Range

Now: $26.27
Low: $25.23
High: $40.37

Volume

11,304,884 shs

Average Volume

41,935,789 shs

Market Capitalization

$148.75 billion

P/E Ratio

72.97

Dividend Yield

6.46%

Beta

0.61